Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
On April 21, the European Commission granted marketing authorization for mCOMBRIAX (mRNA-1083), making it the world's first mRNA combination vaccine for influenza and COVID-19 to receive such approval. Authorized for adults aged 50 and older, the single-dose vaccine is valid across all 27 EU member states plus Iceland, Liechtenstein, and Norway. This milestone marks Moderna's fourth authorized product, aiming to simplify immunization schedules and reduce the burden on healthcare systems by protecting against two major respiratory viruses simultaneously. The approval is supported by pivotal Phase 3 clinical trial data involving approximately 8,000 adults. The study met all primary endpoints, showing that mRNA-1083 elicited statistically significantly higher immune responses against SARS-CoV-2 and three influenza strains (A/H1N1, A/H3N2, and B/Victoria) compared to co-administered licensed flu and COVID-19 vaccines. Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Discusses the Moderna Rally and the Impact of FDA Leadership Changes [Yahoo! Finance]Yahoo! Finance
- Moderna (MRNA) had its price target raised by Barclays PLC from $25.00 to $48.00. They now have an "equal weight" rating on the stock.MarketBeat
- Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)? [Yahoo! Finance]Yahoo! Finance
- Looking for Small-Cap Value? Consider These 2 ETFs [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 2/13/26 - Beat
MRNA
Sec Filings
- 4/6/26 - Form 4
- 3/27/26 - Form SCHEDULE
- 3/16/26 - Form DEFA14A
- MRNA's page on the SEC website